Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
14.91 AUD | +0.20% | +9.55% | +47.92% |
Sales 2024 * | 734M 480M | Sales 2025 * | 911M 596M | Capitalization | 4.92B 3.22B |
---|---|---|---|---|---|
Net income 2024 * | 46M 30.09M | Net income 2025 * | 88M 57.56M | EV / Sales 2024 * | 6.52 x |
Net cash position 2024 * | 129M 84.61M | Net cash position 2025 * | 197M 129M | EV / Sales 2025 * | 5.18 x |
P/E ratio 2024 * |
104
x | P/E ratio 2025 * |
55
x | Employees | 234 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 76.41% |
Latest transcript on Telix Pharmaceuticals Limited
1 day | +0.10% | ||
1 week | +9.44% | ||
Current month | +15.55% | ||
1 month | +16.10% | ||
3 months | +29.52% | ||
6 months | +72.20% | ||
Current year | +47.77% |
Managers | Title | Age | Since |
---|---|---|---|
Andreas Kluge
FOU | Founder | - | 15-10-31 |
Founder | - | 15-10-31 | |
Darren Smith
DFI | Director of Finance/CFO | 58 | 22-01-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Harry McCann
CHM | Chairman | 83 | 17-09-16 |
Founder | - | 15-10-31 | |
Mark Nelson
BRD | Director/Board Member | - | 17-09-16 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
1.39% | 16 M€ | -7.62% | ||
0.04% | 773 M€ | -.--% | - | |
0.01% | 10 M€ | -3.35% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-04-26 | 14.91 | +0.20% | 1 700 410 |
24-04-24 | 14.88 | +4.06% | 1,735,593 |
24-04-23 | 14.3 | +1.42% | 1,508,493 |
24-04-22 | 14.1 | +3.60% | 1,052,608 |
24-04-19 | 13.61 | -0.80% | 1,407,698 |
Delayed Quote Australian S.E., April 26, 2024 at 01:49 am EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+47.77% | 3.2B | |
+1.12% | 42.59B | |
+6.77% | 40.65B | |
+45.26% | 40.57B | |
-11.96% | 26.77B | |
+6.01% | 24.81B | |
-24.92% | 18.17B | |
-3.63% | 11.7B | |
+27.16% | 12.05B | |
+7.30% | 11.1B |
- Stock Market
- Equities
- TLX Stock